Progyny Inc (PGNY) Q4 2025 Earnings Call Transcript

Why It Matters

The results validate Progyny’s scalable, outcomes‑focused model, positioning it for continued growth and stronger shareholder returns amid rising employer demand for fertility and women’s‑health benefits.

Key Takeaways

• Revenue $1.29 B, 10% YoY growth.
• Adjusted EBITDA $222 M, beating guidance midpoint.
• Operating cash flow $210 M, up 17%.
• Client retention near 100%; no single client >9% revenue.
• Progyny Select targeting small fully insured employers, revenue impact 2027.

Pulse Analysis

S. fertility‑benefits market has expanded rapidly as employers seek to offset rising medical costs and support employee wellbeing. Progyny, a specialist provider of family‑building and women’s‑health solutions, leverages a fully managed, per‑member‑per‑month model that bundles clinical care, pharmacy, and support services. By integrating data‑driven care pathways and a national network of clinics, the company has been able to deliver better outcomes—fewer high‑risk pregnancies and lower overall utilization—while keeping employer spend well below the 27 % inflation rate seen in traditional health plans.

Fiscal 2025 results underscore that model’s scalability. 29 billion, a 10 % increase on a reported basis and 20 % when the departed large client is excluded. Adjusted EBITDA climbed to $222 million, surpassing the guidance midpoint, and gross margin expanded by roughly 200 basis points thanks to care‑management efficiencies and economies of scale.

Operating cash flow hit a record $210 million, reflecting a 17 % rise and a high EBITDA‑to‑cash conversion rate that funds ongoing capex, share repurchases, and strategic acquisitions without eroding the balance sheet. 41 billion and adjusted EBITDA up to $239 million, while cutting stock‑based compensation to improve net‑income visibility. The upcoming launch of Progyny Select—designed for small fully insured employers—opens a new addressable market of roughly 50 million lives, though financial contributions are slated for 2027. With a diversified client base, near‑perfect retention, and a cash‑rich balance sheet, the firm is well positioned to sustain growth, return capital through share buybacks, and deepen its foothold in the evolving employer‑benefits landscape.